These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16988582)

  • 21. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
    Johnson DH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
    Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
    Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
    Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
    Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
    Toschi L; Cappuzzo F
    Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?
    Raben D; Bianco C; Milas L; Ang KK
    Semin Radiat Oncol; 2004 Apr; 14(2):139-52. PubMed ID: 15095260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
    Kotteas EA; Charpidou AG; Syrigos KN
    Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
    Khan MH; Alam M; Yoo S
    Dermatol Surg; 2011 Sep; 37(9):1199-209. PubMed ID: 21615602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy for non-small cell lung cancer.
    Toloza EM; D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
    Lara PN
    Clin Lung Cancer; 2006 Jan; 7(4):232-4. PubMed ID: 16512975
    [No Abstract]   [Full Text] [Related]  

  • 34. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.
    Sartor CI
    Nat Clin Pract Oncol; 2004 Dec; 1(2):80-7. PubMed ID: 16264825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor signaling in non-small-cell lung cancer.
    Semrad TJ; Mack PC
    Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
    Saijo N
    Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeted therapies and non-small-cell lung cancer: work in progress?
    Gridelli C
    Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
    Agarwal V; Lind MJ; Cawkwell L
    Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.